Main menu
Common skin conditions
NEWS
Join DermNet PRO
Read more
Quick links
Author(s): Dr Libby Whittaker, Medical Writer, New Zealand (2023)
Previous contributors: Dr Darion Rowan and A/Prof Amanda Oakley, Dermatologists (2018)
Reviewing dermatologist: Dr Ian Coulson
Edited by the DermNet content department
Introduction
Demographics
Causes
Clinical features
Complications
Diagnosis
Differential diagnoses
Treatment
Prevention
Outcome
Bacterial vaginosis (BV) is a common cause of abnormal vaginal discharge resulting from an imbalance of vaginal bacteria. Some patients have findings consistent with bacterial vaginosis on bacteriological culture but are asymptomatic. It is not considered a sexually transmitted infection (STI), although sexual activity is a risk factor.
BV was formerly called non-specific vaginitis or Gardnerella vaginitis.
Bacterial vaginosis affects those with a vagina of reproductive age. Similar laboratory findings are common in postmenopausal women.
A 2019 meta-analysis (Peebles et al) reported the overall prevalence of BV to be 23–29% in women of reproductive age across several regions worldwide.
Epidemiology has been found to vary internationally, as well as by ethnic group. In the United States, for example, the prevalence of BV was highest in black patients (22–51%), followed by Hispanic patients (16–32%), while white and Asian patients had the lowest rates (9–24% and 6–11% respectively). Similarly, in the United Kingdom, antenatal BV prevalence was higher in Afro-Caribbean patients (41%) than white (12%) or Asian patients (6%).
Bacterial vaginosis (BV) is due to a disturbance of normal bacterial equilibrium (or microbiome) in the vagina. It is associated with elevated vaginal pH (>4.5).
Lactobacilli are usually the most common type of bacteria in the vagina. In BV, there is an overgrowth of other (often anaerobic) types of bacteria, especially Gardnerella vaginalis, Mycoplasma hominis, Ureaplasma urealyticum; and Prevotella, Bacteroides, Peptostreptococcus, Mobiluncus, and Clostridiales species.
A study assessing vaginal biopsy specimens found that Gardnerella vaginalis predominated in epithelial biofilms in patients with BV.
BV is not generally considered sexually transmitted or contagious. There is no singular causative organism, and there is no clear equivalent disease in male partners. However, being sexually active is a risk factor for BV, and studies in women who have sex with women suggest that transmission of vaginal bacteria between sexual partners may play a role in some cases.
Other predisposing factors for BV include:
Having an intrauterine device (IUD) may increase the risk of BV, although the association is not entirely clear. Irregular and prolonged vaginal bleeding has been suggested as a potential mechanism, as the pH of blood is also more alkaline than the vaginal pH.
No genetic polymorphisms associated with BV have been identified to date.
Often bacterial vaginosis (BV) is suspected on history taking, particularly in patients with recurrent BV.
In patients presenting with abnormal vaginal discharge, take a sexual history to identify risk factors, and ask about urinary symptoms, vaginal bleeding, chance of pregnancy, and symptoms of pelvic inflammatory disease (PID) such as:
Examination:
Diagnosis is generally confirmed on a vaginal swab. Nugent’s criteria are laboratory-based using microscopy and Gram stain, and are considered the gold standard. Other laboratory methods such as molecular diagnostic assays or nucleic acid amplification tests (NAATs) may be available depending on location.
Point-of-care testing may be used in centres with equipment and training to perform microscopy in-clinic. Amsel’s criteria, for example, is based on saline microscopy, where 3/4 criteria should be met for diagnosis:
Bacterial vaginosis naturally fluctuates and treatment is not always necessary, especially if asymptomatic.
Prevention strategies for bacterial vaginosis (BV) focus on maintaining a normal vaginal pH and balance of bacteria.
Recommendations include:
Some patients may find vaginal health probiotics containing lactobacilli or vaginal acidification (eg, using lactic or boric acid) helpful for BV treatment or prophylaxis, although further high-quality randomised trials are needed to draw clear conclusions regarding their efficacy.
BV is often self-limiting, and generally only requires antibiotic treatment if symptomatic. Symptomatic patients usually respond well to treatment with metronidazole. Recurrence (or treatment failure) can be an issue in up to 58% of patients.
Usually, BV is not associated with serious complications. However, it has been associated with pelvic inflammatory disease; obstetric issues such as preterm delivery if untreated during pregnancy; and it can cause distress and frustration, particularly in those who experience multiple recurrences.